Key Highlights:
- Viatris (VTRS, Financial) shares experienced a premarket drop due to the failure of their blepharitis treatment in a late-stage trial.
- Analysts offer an average price target of $14.16, signaling possible growth from current levels.
- Current consensus rating for Viatris is a "Hold," with a GF Value estimate suggesting minimal upside.
Viatris (VTRS) encountered a setback in its pharmacological endeavors as its promising treatment for blepharitis, pimecrolimus 0.3%, failed to reach its primary endpoints in a pivotal Phase 3 trial. This development prompted an immediate reassessment of the company's strategic direction for this developmental program, affecting the stock's performance in premarket trading.
Wall Street Analysts Forecast
Wall Street analysts have provided a range of one-year price targets for Viatris Inc (VTRS, Financial). The average target stands at $14.16, with projections extending to a high of $35.00 and a low of $8.00. This average target represents a significant 52.72% upside from the current price of $9.27. For detailed estimate data, investors can visit the Viatris Inc (VTRS) Forecast page.
Currently, the consensus recommendation from 11 brokerage firms categorizes Viatris Inc (VTRS, Financial) with an average recommendation score of 2.7, which corresponds to a "Hold" rating. The rating scale is structured from 1 to 5, where a score of 1 signifies a Strong Buy and 5 indicates a Sell.
According to GuruFocus's estimates, the GF Value for Viatris Inc (VTRS, Financial) in a year is projected to be $9.47. This estimate reflects a modest 2.16% upside from the current price of $9.27. The GF Value metric is GuruFocus's assessment of the stock's fair trading value, calculated by examining historical trading multiples, business growth, and estimated future performance. More comprehensive details can be accessed on the Viatris Inc (VTRS) Summary page.
